Please ensure Javascript is enabled for purposes of website accessibility

Down 50%, Is Novavax Stock a Great Buy Now?

By Zhiyuan Sun - Jun 3, 2021 at 9:36AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This coronavirus vaccine drugmaker is having trouble getting its act together -- and has led its investors on a wild ride.

Over the past year, Novavax (NVAX -5.01%) stock has swung between extremely overvalued and extremely undervalued, with a share price ranging from a low of $40.50 to a high of $331.68. It's currently down more than 50% from those all-time highs, which it reached in February. 

Investors were thrilled that the company had developed a solid coronavirus vaccine candidate, but were then shocked by its logistical problems. Is now the time to buy the dip? 

Doctor about to give patient a vaccine.

Image source: Getty Images.

What happened? 

Novavax created its coronavirus vaccine candidate, NVX-CoV2373, using genetic materials that mimic the coronavirus's spike protein, along with an immunoadjuvant (a substance that enhances immune response). In clinical studies, NVX-CoV2373 demonstrated 96% efficacy against the original virus, as well as 86% and 55% efficacy against the U.K. and South African strains.

It's clear that the science behind the vaccine is solid. As an emerging biotech, however, Novavax began encountering problems with production and regulatory filings. To date, NVX-CoV2373 has not received emergency authorization in any country. Meanwhile, the company has had to delay its goal of producing 150 million doses per month all the way from the second quarter of 2021 to the fourth quarter. 

The delay means that Novavax will probably miss the vaccine rollout in G7 countries. As a result, investors began abandoning the stock en masse. 

Is there any hope left? 

On May 6, Novavax executed an agreement with global vaccine alliance Gavi to manufacture and distribute 350 million doses of its recombinant protein-based vaccine to developing countries. Under a separate agreement, the company plans to produce 1.1 billion doses of its vaccine candidate manufactured by the Serum Institute of India (SII). With the facilitation of UNICEF, Novavax transferred its vaccine technology to SII at no cost.

That brings up the main reasons why the stock is undervalued -- its international expansion efforts. While it's true that vaccine demand is plummeting in the U.S., things are not looking so good elsewhere. As of now, only 10% of the world's population has received at least one dose of coronavirus vaccine (it's mostly developed nations boosting that number).

If Novavax manages to get its act together and start producing vaccines by the end of the year, it could very well witness billions in revenue in 2022. The company would have to make some pricing concessions -- say, offering its vaccines at $3 to $4 per dose. However, keep in mind that its market cap has fallen to $10.94 billion and the company still has $2 billion in cash in the bank, giving it an enterprise value of less than $9 billion. That's very cheap for a manufacturer with 2 billion doses in production capacity. 

What's the verdict? 

Given the strength of its coronavirus vaccine candidate, its current valuation, and the growing demand for vaccines beyond the U.S., Novavax stock is an ideal biotech to buy now. Like all other coronavirus vaccine drugmakers, Novavax has the potential to sell more vaccines after the initial rollout completes via booster shots. If you can stomach a lot of volatility ahead, give the stock a chance.


Zhiyuan Sun has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$57.25 (-5.01%) $-3.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.